can create a pro-inflammatory environment resulting in graft injury or loss for tissue transplants, and graft-versus-host disease (GVHD) or donor cell rejection for donor hematopoietic lineage cell infusions.
If the strategy surrounding cancer immunotherapy is focused on harnessing the Yang-the optimized activation and 'heat' in T cells, then in transplantation, we seek the 'cooling' Yin, in focusing on controlling these same co-stimulatory and co-inhibitory pathways, toward the goal of inducing antigen-specific tolerance in T cells rather than T-cell
assault.
In what follows we will review the work in the field of transplant tolerance, highlighting the many successes that have been achieved by targeting T-cell co-stimulatory and co-inhibitory pathways, and discuss the challenges that we still face on the road to the ultimate goal of tolerance-on-demand for all transplant patients. In discussing successes and challenges, we will examine the complexity of manipulating T-cell co-signaling, given that both conventional, effector T cells (Teffs) are targeted by these approaches, along with regulatory T-cell (Treg) populations, for which these manipulations may have opposing biologic effects and hence, transplantation tolerance outcomes. The search for the ideal pathway, which, when manipulated, could simultaneously tilt the balance toward tolerance in both Teffs and Tregs, remains one of the holy grails of our field of inquiry.
Transplantation tolerance is defined as the lifelong acceptance of transplanted organs or cells, in the absence of any immunosuppressive medications, and with preservation of protective immunity. Immune tolerance thus has three major components, all which must co-exist in transplant patients. Each is critical, and all are inter-related, thus raising the bar needed for achieving transplantation tolerance, especially in large animal models and patients. Efforts to blunt co-stimulation pathways in order to accomplish this goal began in earnest over two decades ago, when CTLA4Ig was first synthesized for the purpose of precluding a productive immune response in antigen-activated T cells. [1] [2] [3] [4] These seminal studies demonstrated that this new way of interfering with T-cell co-signaling could potently downregulate T cell and antibody responses to xenogeneic (xeno) and allogeneic (allo) tissues and were heralded in the lay press as having reliably achieved the holy grail of tissue transplantation tolerance. Individual co-stimulatory pathway blockade reports were closely followed by a series of important publications with combination therapy. These included a 1996 study by Dr. Christopher Larsen and colleagues that demonstrated that the coordinated blockade of B7 signaling (through CTLA4Ig) and CD40/CD154 signaling (through an anti-CD154 monoclonal antibody) could produce long-term tolerance to concurrently transplanted skin and cardiac allografts, while preserving the recipient's ability to reject non-donor allografts transplanted after co-stimulatory pathway blockade had been discontinued. 5 Such reports resulted in the birth of combinatorial co-stimulation blockade for generating antigen-specific graft tolerance, a paradigm that continues to be vigorously pursued in the present day. In what follows we provide an overview of this field, as it relates to immune tolerance induction, and discuss the relevant pathways, cells and clinical applications, highlighting where we have been, and where we need to go to make immune tolerance a reality for the patients we treat.
| SIMULTANEOUS BLOCKADE OF B7/CD28 AND B7/CTLA-4: CONFRONTING THE DOUBLE-EDGED SWORD OF CO-STIMULATION AND CO-INHIBITION
The field of co-stimulation blockade began with the search for molecules that paired with antigen-specific TCR stimulation to optimize T-cell activation after cognate antigen recognition. To accomplish this, researchers used agonistic monoclonal antibodies directed at newly identified T-cell surface molecules, and identified the immunoglobulin (Ig)-superfamily member CD28 as a critical T-cell co-signaling molecule which was required to optimally initiate, amplify, and sustain T-cell responses. 6 Subsequent studies demonstrated that there were two distinct CD28 ligands, CD80 (B7-1) and CD86 (B7-2), that were expressed as dual coreceptors on antigen-presenting cells (APC).
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While this was a central discovery, the complexities of signaling through this pathway and its surrogates is still incompletely under-
stood, yet key to ongoing efforts to target the CD28 pathway to control T-cell activation.
The first reagent used to inhibit CD28 signaling was developed by Linsley et al. 12 , who developed a soluble CD28Ig, reasoning that it could block CD28 signaling by providing an alternative binding site for CD28 ligands. While the data supported this molecule as the first 'costmulatory blockade' reagent, its affinity for the ligand(s) of CD28 was relatively low such that in vivo experiments (and clinical applications) with this reagent were not sufficiently encouraging for further testing. At this time, a molecule with molecular similarity to CD28, named cytotoxic T lymphocyte antigen-4 (CTLA-4), now also known as CD152, was discovered Dr. Pierre Goldstein at the Pasteur Institute. 13, 14 CTLA-4 was first presumed to act as stimulator of T-cell activation. However, further studies by several laboratories subsequently showed that, while CTLA-4 was upregulated during T-cell activation, the signal delivered by CTLA-4 engagement functioned as a negative, rather than positive regulator of T-cell function. 15, 16 Given the shared structure between CTLA-4 and CD28 as well as B7 ligand binding (and prior to its unequivocal identification as a negative regulator of T-cell function), 14 a CTLA4Ig fusion protein, consisting of the extracellular domain of CTLA-4 fused to an IgG tail (to prolong its half-life), was developed, with the hopes that CTLA4Ig-mediated blockade of positive T-cell co-signaling would dominate over blocking the CTLA-4 inhibitory pathway. Dr. Peter Linsley and colleagues indeed showed that CTLA4-Ig was capable of binding B7 at clinically relevant concentrations and in doing so, inhibited T-cell alloproliferation and T-dependent B-cell antibody production. 4 This breakthrough discovery ushered in the era of T-cell modulation for clinical control of undesired, aggressive donor and host T-and B-cell immune responses that precluded transplantation tolerance. As briefly mentioned above, in vitro characterization studies with CTLA4Ig were quickly followed with demonstrations of the ability of CTLA4Ig to modulate allo-and xenoimmunity in vivo, including producing striking prolongation of xeno-islet graft survival in mice. 2, 3, 17 While further studies in mice, non-human primate (NHP), and patients have indicated that this agent is not capable of producing tolerance, these first in vivo studies were striking in their demonstration of the impact of this first targeted costimulation blockade approach in small animal model systems.
Given the ability of CTLA4Ig to impact both T-and B-cell function, solid organ and hematopoietic stem cell transplantation (HCT). In HCT, our work and that of others in murine, canine and NHP models suggested that abatacept has biologic activity in preventing GVHD.
32-37
This led to a promising first-in-disease feasibility trial 38 which demonstrated the pharmacodynamic impact of abatacept in controlling T-cell proliferation early post-transplant, providing the foundational data for our ongoing Phase II study designed to evaluate the efficacy of abatacept in preventing severe GVHD after either mismatched or matched unrelated donor HCT (Clinicaltrials.gov # NCT01743131).
In solid organ transplant, although the abatacept formulation of CTLA4Ig showed significant promise in murine models, 39-51 including evidence for a critical role in immune tolerance when combined with CD154-based co-stimulation blockade (discussed in detail below), initial studies in NHP renal transplant models were underwhelming. 52, 53 These results may have been mechanistically linked to the fact that CD28 and CTLA-4 compete for B7 ligands (CD80 and CD86) that are required for CD28 activation, and that the interaction of CD80 with both CD28 and CTLA-4 appears substantially better than that of CD86.
Because abatacept has decreased affinity for CD86 compared to CD80, CD80/CD86 interactions with CD28 and CTLA-4 may be incompletely blocked with the abatacept formulation of CTLA4Ig. 12 Therefore, the group at Bristol-Myers Squibb, in collaboration with Larsen's group at the Emory Transplant Center decided to create directed mutations in the CTLA4Ig molecule designed to increase its affinity for CD86. 52 The resulting formulation, differing in two amino acids from abatacept (known first as LEA29Y and subsequently as belatacept, and now marketed as Nulojix™), increased both affinity and avidity of CTLA4Ig toward both B7 molecules. In doing so, belatacept resulted in increased blockade of both CD28-and CTLA-4 mediated T-cell activation in vitro and prolonged allograft survival in NHP models when compared to abatacept. 48, 52 A subsequent series of Phase II and Phase III trials in renal transplant patients demonstrated that belatacept led to improved long-term renal functional outcomes after transplant and fewer off-target toxicities.
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These results have been verified in long-term follow-up studies.
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Two important observations from the belatacept trials point to important biological complexities of targeting T-cell co-stimulation using CTLA4Ig: First was the observation that patients treated with a low-intensity regimen of belatacept actually had superior graft outcomes than those treated with a higher intensity regimen. 54 Second was the observation that while overall results were improved with belatacept, patients treated with this drug experienced higher rates of early (reversible) rejection events. [54] [55] [56] [57] There are two potential explanations for these observations: First, is the fact that belatacept, like abatacept, not only targets CD28 positive co-signaling but also targets CTLA-4-based co-inhibition. CD28 is a highly expressed but low-affinity receptor, in contrast to CTLA-4, which is in low abundance but is a higher affinity receptor. At high in vivo concentrations, both CD28 and CTLA-4 would be blocked, whereas at lower in vivo con- [75] [76] [77] [78] [79] [80] [81] Importantly, FR104 performed superiorly to belatacept in NHP models of renal transplant 80 and human xeno-GVHD. 76 The mechanisms that were critical for this improved activity have not been determined, although experiments in both systems suggest that both CTLA-4-and Treg-mediated mechanisms may be operative. 76, 77, 80 FR104 is also now in clinical trials, being studied in patients with RA.
| CD40:CD154-DIRECTED CO-STIMULATION BLOCKADE: THE STORY OF ON-TARGET POTENCY BEING SIDELINED BY AN UNEXPECTED TOXICITY
In preclinical studies, there has been no class of molecules that has seen more success in transplant tolerance induction than those that target CD40: CD154 signaling. CD40 (a member of the tumor necrosis factor receptor (TNFR) superfamily, expressed on most APCs), and its ligand, CD154 (expressed primarily on activated T cells, and also found on other hematopoietic cells, discussed below) are critical for T-cell function, as well as for the B-and T-cell interactions that result in the generation of high affinity antibodies that can be pathological in solid organ transplantation and HCT. 82 Consistent with its TNFR structure, CD40 signaling depends on its interactions with TNFR-associated factors (TRAFs), 83 which when engaged, lead to T-cell activation through a variety of secondary signals, including NF-kB, Jnk, and AKT pathways. 82 The importance of CD40:CD154 engagement likely is due to its critical impact both on T-cell activation and on the initiation and perpetuation of the germinal center response in lymph nodes, thus being a critical hub for both T-and B-cell immunity. 84, 85 The potential translational importance of targeting this pathway has been demonstrated numerous times, in murine, canine, and NHP models. The early studies concentrated on blocking CD154, and led to the striking result that a single dose of the MR1 anti-CD154 mAb permitted long-term cardiac transplant acceptance when combined with donor splenocyte infusion, and that anti-CD154 mAb infusion led to skin acceptance in mice. 86, 87 In addition, striking synergy was observed when blockade of CD154
was combined with B7 blockade (using CTLA4Ig), which was demonstrated in numerous publications, including the seminal observation of its ability to lead to tolerance to both heart and skin allografts in the allogeneic Balb/c→→ C3H model. 86 The impressive results in mice led to a large number of studies in NHP. In those studies, anti-CD154 antibodies were a critical component for the prolonged acceptance of both bone marrow and renal allografts. 67, [102] [103] [104] [105] While the induction of true immune tolerance in mice was not able to be directly extrapolated to NHP, CD154 blockade results were sufficiently impressive that they led to widespread interest in the clinical translation of CD154-directed therapies, as potential adjuncts to both conventional immunosuppression and CTLA4Ig-based therapeutics.
Unfortunately, the clinical translation of the first anti-CD154 antibodies was halted quickly, when thromboembolic complications were noted. This was found to be due to the expression of CD154 on activated platelets, leading to anti-CD154-mediated platelet activation and clotting in treated patients. 
| ICOS/L, A SUPPORTING PLAYER IN GERMINAL CENTER TARGETING AND CO-STIMULATION BLOCKADE
Structurally similar to CD28, inducible T-cell co-stimulator (ICOS, also known as CD278) is also an Ig superfamily member, expressed as a homodimer in activated (but not resting) T cells, as well as NK and NKT cells. [122] [123] [124] As with CD28, binding of ICOS to its ligand, CD275, results in T-cell activation, including expanded T-cell proliferation, survival, cytokine production, and effector differentiation.
125-127
Consistent with these properties, ICOS blockade inhibited murine acute GVHD induced by CD4 + and/or CD8 + T cells and also was shown and in a murine model of chronic GVHD model induced by injecting parental splenocytes into unirradiated F1 recipients, antiICOS mAb inhibited B-cell activation, autoantibody production and glomerulonephritis, the primary manifestation of chronic GVHD in that model system. 136 In addition, using a murine multi-organ system model of chronic GVHD with a hallmark of lung and bronchiolitis obliterans that is due to antibody production and depostion, blockade of ICOS in mice with active chronic GVHD restored pulmonary function to the level seen in no-GVHD controls. 137 In that setting, ICOS/L blockade resulted in a significant reduction in germinal center formation, essential for chronic GVHD generation in that model system.
Whether these encouraging results in mice and canine models will be translatable to the clinic is unclear. Indeed, a recent study showed that in a NHP renal transplant model, ICOS blockade did not prolong allograft survival, either as a monotherapy or when combined with belatacept. 138 However, combination blockade of this pathway with
other potential partners was not tested in this study, nor was a comprehensive examination of its impact on diseases that are more reliant on GC formation. The mixed results notwithstanding, an anti-ICOSL antibody (AMG-557) is currently in clinical trials for lupus (Clinicaltrials.
gov # NCT01683695 and NCT00774943), and as such, a direct test of the impact of ICOS pathway blockade in patients is being undertaken.
| TARGETING OX40:OX40L: AN ADDITIONAL AVENUE FOR THE 'RIGHT' TARGETING OF TCONV AND TREGS?
Given the complexities of the impact that co-signaling pathway blockade makes on both conventional and regulatory T-cell populations, the search for the ideal therapeutic continues in the fields of both autoimmunity and transplantation. New studies are identifying a role for OX40 (CD134):OX40L (CD252) blockade in transplant immunomodulation, given that, like CD154 pathway blockade, it may be able to simultaneously control Tconv effector function while potentially permitting Treg homeostasis and function. It has been well documented that OX40 is upregulated on CD4»CD8 cells during T-cell activation. [139] [140] [141] [142] In several murine acute GVHD models, OX40:OX40L
blockade augmented survival associated with anti-host hyporesponsiveness with the major effects being seen on CD4 + T cell-mediated acute GVHD. [143] [144] [145] [146] [147] OX40 is also upregulated on human alloreactive T cells, and depletion of CD134 + T cells during an allogeneic mixed lymphocyte culture reaction with HLA mismatched stimulator cells dramatically reduced anti-host but not anti-third party alloresponses. 148 In the context of solid organ transplantation, blockade of OX40:OX40L signals was shown to prevent allograft rejection in murine models, in a manner that is non-redundant with blockade of CD28 or CD154. 149 Of note, several of the murine solid organ allograft studies showed that OX40:OX40L blockade did not impact T-cell prolifer- post-transplant to treat or prevent leukemia relapse. 160 Consistent with these murine data, selective depletion of human alloreactive T cells after a mixed lymphocyte reaction was highly effective in reducing alloresponses. 161 In parent-into-F1 unirradiated GVHD models, blocking anti-CD137 mAb ameliorated acute GVHD, while unfortunately enhancing chronic GVHD associated with reduced CD8 + T cells expansion and IFNg expression along with enhanced antibody production.
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In solid organ allograft models, using 4-1BBL-deficient recipients, skin allograft survival was not prolonged, and the combination of 4-1BB and CD28 deficiency only slightly delayed rejection kinetics. 163 These data suggest that 4-1BB was not the main pathway of escape in the absence of CD28 signaling. Despite the lack of striking effect of the genetic absence of 4-1BBL, blockade of the pathway has had positive impact on allograft survival in mice, prolonging corneal, intestinal, and cardiac allotransplants. [164] [165] [166] [167] Signaling through 4-1BB
and its ligand therefore clearly play a role in alloimmunity; however, its supporting role in this process has thus far hindered its pathway toward the clinic for control of T-cell activation, quite distinct from the central role it has played in CAR-mediated T-cell activation and subsequent tumor clearance.
| BLOCKADE OF T-CELL TRAFFICKING TO SECONDARY LYMPH NODES AND TARGET ORGANS AND TISSUES: IMPACT ON TRANSPLANT OUTCOMES AND INTERACTIONS WITH CO-SIGNALING BLOCKADE
One of the most critical steps in both organ transplant rejection and GVHD pathogenesis is the recruitment of activated T cells to target organs. As such, there is high interest in the impact that adhesion and chemokine blockade may have on both processes. Much of the work on adhesion blockade has been pioneered in autoimmune disease, where several targeted therapies have been investigated. [168] [169] [170] [171] [172] [173] These include blockade of the lymphocyte function antigen-1 (LFA-1; CD11a) pathway, the alpha4 (CD49d), beta 1 (CD29) integrin very late antigen-4 (VLA-4) pathway, and the sphingosine-1-phosphate receptor (S1P1R) pathway that controls lymphocyte egress from lymph nodes and can be blocked by the S1P1R antagonist, FTY720.
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While the predominance of the published data suggest important roles for both LFA-1 and VLA-4 pathway blockade in improving GVHD and graft acceptance, 176, 177, [197] [198] [199] the latter analyzed in murine, NHP, and patient trials, the significant risk of infectious disease with both these agents has limited their use in transplant settings. 184 Thus, while LFA-1 blockade has shown some promise in both murine and some, but not all NHP studies, and was also included in several islet trans- As with anti-LFA-1 and anti-VLA4, there is also evidence to suggest that FTY720 can prevent acute GVHD, and at least temporarily prevent rejection as assessed in preclinical murine models of transplantation. [200] [201] [202] [203] [204] [205] [206] [207] [208] [209] [210] [211] [212] [213] [214] In murine acute GVHD systems, FTY720 has been shown to prevent GVHD lethality without impairing graft-versuslymphoma or -leukemia effects. Mechanisms in these studies have been attributed to impairing lymphocyte migration, inducing donor anti-host alloreactive T-cell apoptosis, and reducing splenic CD11c As with the adhesion and egress inhibitors, there has been significant interest in blocking chemokine-chemokine receptor interactions to improve transplant outcomes. Of the many chemokines that could be targeted, CCR5 has been investigated most thoroughly, after having been shown to be a central molecular mediator of T-cell trafficking to GVHD target organs, including the GI tract. 217, 218 In preclinical studies, CCR5 blockade has shown protection against GVHD in sublethally irradiated recipients, associated with reduced homing to the intestinal Peyer's patches in some models using knockout donor T cells, 217, 219 and, somewhat paradoxically, acceleration of GVHD in heavily but not lightly irradiated recipients. 219, 220 Based upon the positive data in murine non-myeloablated recipients, the CCR5 inhibitor maraviroc (NCT00948753), an FDA-approved drug designed to limit CCR5-mediated HIV entry into CD4 T cells, was given for 1-month post-transplant, along with standard-of-care pharmacological agents, to high-risk patients receiving matched unrelated or one antigen mismatched unrelated donor grafts. Although acute GVHD of the skin was not eliminated, patients given maraviroc had a low incidence of GI and liver GVHD which constituted one of the first demonstrations of a target organ-specific effect of a biologic anti-GVHD prophylaxis regimen. 221 The durability of the impact of maroviroc on GVHD control is still undetermined, however, and there may be conditioning-regimenspecific effects in patients as seen in rodent models. 219 This agent is now being investigated as part of a large multicenter study sponsored by the BMT-CTN (Clinicaltrials.gov # NCT02208037), where issues of conditioning and durability of the GVHD protective effect will be investigated more thoroughly.
| LFA-3 (CD58): CD2 BLOCKADE: A MISSED OPPORTUNITY?
In 
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The clinical benefits of anti-CD2 mAb could be seen in studies in both bone marrow transplant 225 and Type I diabetes 226, 227 indicating the potential importance of this pathway in controlling T cell-mediated disease. However, although alefacept is currently FDA approved for the treatment of psoriasis, the parent company for the marketed version of the drug decided to discontinue marketing this drug in 2011 for financial reasons, making future clinical applications uncertain.
Given the wide array of indications in which this agent may have significant activity, and its potentially unique predisposition for memory, rather than naïve T cells, this likely represents a missed opportunity, and one that the transplant and autoimmune communities would welcome revisiting.
| THE CENTRAL ROLE OF TREGS IN TRANSPLANT TOLERANCE
In solid organ transplant models, it is clear that achieving long-term allograft survival and/or tolerance through the manipulation of cosignaling pathways is associated with an expansion of Tregs. 228 What is less clear, however, is whether this is a specific result of blocking co-stimulatory pathways per se, or rather, a secondary effect of antigen presentation in an environment where inflammation has been deliberately suppressed, promoting the expansion of pre-existing Tregs 
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These data underscore the central role that Tregs play in both establishing and maintaining successful engraftment, and in restraining alloreactivity. Thus, in an era of manipulation of T-cell co-signaling with targeted therapies, choosing those that 'walk the fine line' of restraining effector T-cell activation while supporting Treg reconstitution and function will likely be necessary in order to achieve immune tolerance after both solid organ and HCT.
| THE KEY ROLE OF MEMORY T CELLS IN ESCAPING CO-STIMULATORY PATHWAY BLOCKADE AND APPROACHES TO PREVENT TMEMORY CELL ESCAPE
As noted above, CD28 is required for optimal activation, function, and Studies to overcome pre-existing memory have focused on non-CD28-mediated pathways. Preclinical studies in mice suggest that OX-40 may be a useful target, 254 and data in non-human primates points to CD2 as a potential useful target for memory T cells. 224 As noted above, this has been supported by an early-phase clinical study in type I diabetes suggesting that using LFA3Ig (a soluble CD2-ligand) may deplete Teffector/memory cells and/or promote T-cell exhaustion. 
| PD-L1 VS PD-L2: PREDOMINANCE OF PD-L1 DUE TO MORE PROMISCUOUS TISSUE EXPRESSION?
In its negative regulatory functionality, PD-1 is known to interact with both PD-L1 and PD-L2, and the relative importance of these ligands has been a matter of significant investigation. PD-L1 (B7- 
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Another potential explanation for the predominance of PD-L1 signaling in controlling allograft acceptance came from the discovery that PDL1 (and not PD-L2) can interact with CD80 in addition to PD1. 276 In acute GVHD, PD-L1/CD80 interactions induce apoptosis of donor T cells in a PD-1-dependent manner, resulting in amelioration of GVHD. Similarly, PD-L1/CD80 interactions can control diabetogenic Teffs. Thus, PDL1 may provide a parallel track for the control of alloreactivity that renders it as a central player in allograft survival.
Evidence for this role was further strengthened by the identification of a monoclonal antibody that specifically targets the PDL1:CD80 binding motif, providing a structural basis for the previously identified biologic activity. 268 
| THE DOWNSIDE OF BLOCKING CO-INHIBITORY RECEPTORS: UNWANTED T-CELL ACTIVATION, GVHD, AUTOIMMUNITY
While this review is focused on manipulation of co-stimulatory and co-inhibitory molecules to control rather than stimulate T-cell function, it is important to consider the impact of these agents on both auto-and alloimmunity, as patients at risk for both these processes are now being treated with checkpoint blockade agents. There have now been several reports of immune activation syndrome in patients treated with both anti-CTLA-4 (ipilimumab) and anti-PD-1 (novolumab). These include evidence for pulmonary, skin, cardiac, hepatic, GI, and bone marrow disease. [277] [278] [279] [280] [281] [282] The range of clinical severity of these diseases is large, and unfortunately includes some patients who have required extensive hospitalization and treatment with broad-acting immunosuppressive drugs, with patient death occurring in some instances. However, there are also numerous reports of patients with de novo inflammation or flare of known autoimmune disease being successfully treated with conventional immunosuppression while continuing to receive checkpoint blockade. Indeed, earlyphase data showed that administration of ipilimumab was feasible in patients with recurrent hematologic cancers after allogeneic HCT, and resulted in durable responses, especially of extramedullary acute myeloid leukemia, although immune-mediated toxic effects and GVHD occurred. 283 In other studies, PD-1 pathway blocking reagents have been used to treat relapse post-allo-HCT, although early data do point to higher acute GVHD incidence and severity in treated patients. 284 It is still not clear what the impact of combining these two opposing therapies will be on tumor biology, as a large enough study has not yet been undertaken, but, at least in melanoma and small cell lung cancer, pre-existing autoimmunity is not considered an absolute contraindication for treatment with checkpoint blockade.
The issue of intercurrent alloactivation during checkpoint blockade or CAR-T therapy is also critical to the design of relapse-prevention strategies for patients that have undergone allogeneic BMT. In these patients, there is concern about the risk of induction or exacerbation of GVHD with checkpoint blockade, and it is not currently offered clinically. Although murine studies have suggested that GVHD can occur with allogeneic CAR therapy in the setting of transplant, 285 this has not been a major problem in patients, and many post-allo-BMT patients are treated with CAR-T cells. 286 However, there is concern with giving CAR-T cells in post-transplant patients who are being treated for GVHD, and this is not currently standard practice, given the concern of exacerbating GVHD with these therapies. There is also a concern for negatively impacting the efficacy of CAR-T cells when patients are receiving treatment with steroids and other agents to control GVHD. Engineering CAR-T cells to be resistant to these agents may increase the application of this therapy post-transplant. However,
given the potential hazard of having a T-cell population that cannot be controlled by conventional immunosuppression, 287 having a suicide trigger engineered into these T cells is considered a necessary safety criteria.
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| CO-INHIBITORY LIGANDS OTHER THAN CTLA-4 AND PD-1
In addition to CTLA-4 and PD1 − , another of the major co-inhibitory molecules, LAG-3, has also become a major target for checkpoint blockade, with trials of anti-LAG-3 antibodies in glioblastoma, other solid tumors as well as hematologic malignancies. [290] [291] [292] In immune tolerance studies, its expression on induced Tregs is upregulated by exposure to IL-27 and is critical for the optimal function of these cells in controlling autoimmune diseases. 292, 293 In acute GVHD, studies have shown that LAG-3 KO Tconv induce significantly more severe GVHD than wildtype Tconv and that the absence of LAG-3 on CD4
but not CD8 T cells is responsible for worsening GVHD. found to lack B7-H3 messenger RNA. 297, 298 Similar to B7-H3, B7-H4 is another B7 family member that is a negative regulator of T-cell responses. This molecule is expressed on tumors and can be associated with a poor prognosis. Although GVHD studies have not been reported to date, B7-H4 expression has been shown in multiple studies to prolong islet allografts and in CD28-deficient recipients, B7-H4 blockade resulted in accelerated cardiac allograft rejection associated with increased frequencies of IFNg, IL4, and granzyme B-producing splenocytes. 299 Moreover, the efficacy of CTLA4Ig in promoting allograft survival was diminished in mice that did not have an intact B7-H4 pathway. B7-H4 agonistic reagents are not clinically available at this time.
2B4 (CD244, SLAMf4) is also a central co-inhibitory molecule.
Although it was originally identified on NK cells, it is clear that 2B4
is upregulated on activated T cells. 
| THE SPECIAL ROLE OF LARGE ANIMAL MODELS IN UNDERSTANDING CO-SIGNALING IN TRANSPLANTATION
Most of the pathways and molecules involved in T-cell co-signaling have been first identified in murine models, using both genetic knockout technologies and antibody-and small molecule-based blockade.
While these murine studies have been absolutely critical to the progress in the field, canine models 135, 213, [317] [318] [319] [320] [321] [322] and NHP models 323 has not yet been identified, ongoing studies in mice and NHP focused on identifying the causative mechanisms, and using a range of agents designed to overcome these early rejection responses is underway.
The utility of NHP models in moving co-stimulation blockade to the clinic has also been demonstrated in the field of BMT. While the success of both abatacept in RA and belatacept in renal transplant should have predicted the utility of these approaches in bone marrow transplant (along with the murine data that supported a role for this pathway in the pathogenesis of acute GVHD), 32-37 until the demonstration of the activity of CTLA4-Ig in preventing alloreactivity in a canine 318 an NHP model, 33 there was hesitation in the field to use in vivo co-stimulation blockade as a novel approach for GVHD prevention (There had been one trial of ex vivo exposure of bone marrow products to either CTLA4Ig or anti-B7 antibodies, 324 but this was not followed with significant adoption by the BMT field.) The demonstration in NHP that combination co-stimulation blockade could significantly protect recipients from GVHD provided the necessary rationale for clinical translation of this strategy to patients. 38 We are now completing a large Phase II study (Clinicaltrials.gov# NCT01743131) designed to determine both the benefits and risks of the addition of abatacept to standard-of-care GVHD prophylaxis in both adult and pediatric transplant patients. gov # NCT00001857) and one for patients with lupus neprhritis.
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However, both clinical trials were halted shortly after their initiation,
given an unusually high rate of thromboembolic complications in treated patients.
Subsequently, Kawai et al. 109 reported a new regimen that incorporated antiCD154 antibodies in NHP that also demonstrated the thromboembolic events; however, many previous studies had failed to identify this complication. The combined lessons with anti-CD28 and anti-CD154 have pushed the field of NHP transplantation research to evolve more stringent practices for evaluating the potential toxicity and efficacy of therapeutics prior to clinical translation, and the road to the clinic through primate investigation has continued to be robust.
Following the identification of the thrombosis risk with anti-CD154, there was a significant push to develop and evaluate anti-CD40 reagents in NHP for use in transplantation, and these studies suggested that targeting CD40 had significant efficacy, on par with that observed for CD154-directed therapies. These NHP results are now being translated to the clinic, with the first anti-CD40 antibodies being tested for psoriasis and renal transplantation (clinicaltrials.gov # NCT01585233, NCT01780844 and NCT02217410). In addition, the thromboembolic complications with the conventional anti-CD154 antibodies have now been overcome, with domain-specific, single-chain antibodies (rigorously determined to not induce thrombosis), having been developed. These are being re-introduced into the fields of both autoimmunity and transplantation with high hopes for significant efficacy without toxicities.
The experience with both anti-CD28 and anti-CD154 antibodies have reinforced the contention that no animal model is a perfect surrogate for carefully conducted clinical trials. However, the strengths of NHP models have been critical for the streamlining of translation of co-stimulation blockade to the clinic for autoimmunity and transplantation. These studies permit combination therapies that are more difficult to interrogate in murine models, given significant differences in pharmacokinetics and in receptor:ligand expression patterns in mice compared to humans. They also permit the direct evaluation of reagents that are developed for human use, which usually cross-react with NHP targets but rarely do so with their murine counterparts.
Finally they permit intensive monitoring of both the blood and transplant target organs (eg, kidney, heart, skin, GI tract) such that both the peripheral and tissue-specific immunologic consequences of transplant and novel therapeutic strategies can be fully assessed. This is essential for both the evaluation of safety and efficacy, with the proviso that careful attention be paid to any species-specific heterogeneity of target expression, as occurred with TGN1412.
In order to maximize their utility for clinical transplantation, the field of NHP experimentation has greatly benefited from recent advances that help assure that the immune milieu of these transplants is understood in the greatest detail possible. One significant example is the establishment of a new 'gold standard' in transplant studies, where the degree of MHC disparity between donors and recipients is now expected to be defined, and equivalent among different treatments in any transplant series. 102, 333 Until 2010, this degree of information about the MHC was not included in transplant planning, which opened up these studies to the potential confounder of serendipitously close MHC matching leading to transplant outcomes that were more successful than they otherwise would have been (or vice versa with highly disparate transplant pairs).
Our group and others created a new paradigm in NHP transplant planning by applying first microsattelite-102, 333 and now MHC-allele-level typing to multiple NHP colonies, 334 with the NIAID providing critical support for this effort, by funding the detailed MHC typing of their sponsored macaque colony. In addition to the rigorous MHC matching that is now possible in NHP transplant experiments, the detailed annotation of the rhesus transcriptome 335, 336 has allowed a systems approach to understanding the impact that new therapies make on the T-cell transcriptional networks controlling transplant outcomes. This has led to new insights about the breakthrough alloreactivity 336 that occurs with both standard and CTLA4Ig-based immunomodulation for GVHD prevention, as well as the identification of new potential targeted therapies to control the T-cell activation that leads to GVHD. 337 These advances have helped solidify the depth of analysis that is possible with NHP models of T-cell co-signaling, thereby helping to optimize the ability of these models to most efficiently advance novel targeted therapeutics to the clinic.
| CONCLUSIONS AND PERSPECTIVES
In this review, we have discussed the co-signaling pathways that lead to T-cell activation. However, our focus has not been on controlling these pathways in order to activate T cells, or awaken them from senescence (what one might call harnessing the 'Yang' in T cells) but rather, we have concentrated on the field of immune tolerance, a field that is focused on the Yin, or the specific 'cooling' of T cells, to control T-cell activation and to lead to lifelong acceptance of allografts, without the need for ongoing immunosuppression. This work has its philosophical underpinnings in the landmark work of Billingham, Brent, and Medawar, over 60 years ago, which introduced the concept that under some conditions, lifelong acceptance of foreign cells and tissues could occur. 338 As we have learned more about the complex molecular networks that control T-cell activation, and T-cell tolerance, two things have happened:
First, we are more and more able to manipulate T-cell programming to achieve our goals (whether they be T-cell activation or T-cell tolerance) and second, we are increasingly aware of the extremely delicate balance that exists, that makes these manipulations extremely difficult to fully control. This has been shown in both the fields of cancer immunotherapy and in immune tolerance work. In cancer immunotherapy, we have seen toxicities directly attributable to our unleashing of T-cell activation in a manner that has many fewer brakes than exist in the natural setting. In immune tolerance, we have seen the consequences of 'over-cooling' of T-cell immunity, which can lead to defects in protective immunity against both infectious pathogens and tumor cells. Moreover, our increasing awareness of the impact of manipulating T-cell co-signaling pharmacologically, affecting both effector and regulatory T cells, has led to an understanding that we must induce immune tolerance on a 'knifes-edge':
We must seek to understand in exquisite detail the complex systems that control T-cell programming such that we can simultaneously induce tolerance in all T-cell subpopulations, both effector and regulatory. The ongoing work in murine NHP and patient trials are geared toward just this goal: understanding the programming that naturally induces tolerance, and recapitulating this with targeted therapies such that we induce just the right amount of Yin for our patients undergoing transplantation.
